The Cyprus Association of Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) commends the decision of the Cabinet to approve the implementation proposal of a National Health System (GESY) in Cyprus, which was presented by the Ministry of Health in collaboration with the Ministry of Finance.
KEFEA believes that the implementation of GESY will pave the way for solving major problems facing the health sector in Cyprus, and is expected to have significant benefits for the state, but mainly for Cypriot patients.
With the introduction of GESY, Cyprus satisfies one of the key recommendations of the European Commission for the implementation of a financially sustainable health system, which will reduce disparities between public and private sectors, guarantee to provide high quality health services and at the same time, allow access to innovative medicines for all Cypriot patients.
Finally, KEFEA, a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), is committed to providing any additional support at its disposal at a European level in order to help the Cypriot authorities in their efforts to create a better National Health System.
Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA)
The Cyprus Association of Research & Development Pharmaceutical Companies (KEFEA) was founded in 2006 as the representative body of multinational pharmaceutical companies in Cyprus. Its members are GSK, Lilly, MSD, Novartis, Pfizer, Sanofi and Janssen, altogether employing more than 140 people in Cyprus. It is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). KEFEA’s mission is to provide Cypriots with quality healthcare and access to new medicines. Its objectives are to ensure uninterrupted access to medicines at reasonable prices in the Cyprus market, given the acknowledgement of budgetary constraints, provide scientific educational information on diseases and treatments to healthcare providers, ensure that European objectives regarding high healthcare standards are implemented in the Cyprus market, and comply with a common code of ethical practice.